253
Views
6
CrossRef citations to date
0
Altmetric
Clinical Features - Case Report

Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

, , , &
Pages 239-240 | Received 20 Dec 2018, Accepted 25 Jan 2019, Published online: 08 Feb 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Murlidhar Rajagopalan, Sunil Dogra, Abir Saraswat, Sachin Varma & Pravin Banodkar. (2021) The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios. Psoriasis: Targets and Therapy 11, pages 109-122.
Read now

Articles from other publishers (5)

Ana Sanader Vucemilovic, Marina Krnic Martinic, Elvira Lazic Mosler & Livia Puljak. (2023) Pain associated with psoriasis: a qualitative study. Pain Medicine.
Crossref
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, Federica Li Pomi, Ylenia Ingrasciotta, Giuseppe Nunnari & Claudio Guarneri. (2022) Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 10:2, pages 228.
Crossref
Giovanni Paolino, Santo Raffaele Mercuri, Pietro Bearzi & Carlo Mattozzi. (2020) Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS‐CoV ‐2 ( COVID‐19 ) pandemic emergency: A quick review for a quick consultation . Dermatologic Therapy 33:5.
Crossref
Alessandro Santaniello, Barbara Vigone & Lorenzo Beretta. (2020) Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients. Metabolism 110, pages 154300.
Crossref
E. Yu. Loginova, Yu. L. Korsakova, A. D. Koltakova, E. E. Gubar, P. L. Karpova, S. I. Glukhova & T. V. Korotaeva. (2019) The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice. Rheumatology Science and Practice 57:3, pages 299-306.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.